Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Short-term Investments (2020 - 2025)

Mirum Pharmaceuticals (MIRM) has 6 years of Short-term Investments data on record, last reported at $86.6 million in Q4 2025.

  • For Q4 2025, Short-term Investments rose 49.87% year-over-year to $86.6 million; the TTM value through Dec 2025 reached $86.6 million, up 49.87%, while the annual FY2025 figure was $86.6 million, 49.87% up from the prior year.
  • Short-term Investments reached $86.6 million in Q4 2025 per MIRM's latest filing, down from $93.5 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $149.6 million in Q3 2022 and bottomed at $3.0 million in Q3 2023.
  • Average Short-term Investments over 5 years is $86.4 million, with a median of $84.6 million recorded in 2023.
  • Peak YoY movement for Short-term Investments: crashed 98.01% in 2023, then skyrocketed 1969.2% in 2024.
  • A 5-year view of Short-term Investments shows it stood at $125.2 million in 2021, then dropped by 1.19% to $123.7 million in 2022, then tumbled by 97.6% to $3.0 million in 2023, then surged by 1845.88% to $57.8 million in 2024, then skyrocketed by 49.87% to $86.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Short-term Investments were $86.6 million in Q4 2025, $93.5 million in Q3 2025, and $76.4 million in Q2 2025.